Nanobiotix Competitors

Stocks . USA . 
Stock . Nanobiotix
NBTX Stock  USD 23.12  1.45  6.69%   
Nanobiotix competes with GH Research, ARS Pharmaceuticals,, Savara, Tyra Biosciences, and Rezolute; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Nanobiotix competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Nanobiotix to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Nanobiotix Correlation with its peers.
For more information on how to buy Nanobiotix Stock please use our How to Invest in Nanobiotix guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Nanobiotix competition on your existing holdings.
  
Build AI portfolio with Nanobiotix Stock
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nanobiotix's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
14.0222.6631.30
Details
Intrinsic
Valuation
LowRealHigh
10.5719.2127.85
Details
Naive
Forecast
LowNextHigh
16.9825.6234.26
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
21.4422.5223.61
Details

Nanobiotix Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Nanobiotix and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Nanobiotix and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Nanobiotix does not affect the price movement of the other competitor.

High positive correlations

TYRA
+ 0.88
SVRA
EYPT
+ 0.82
TYRA
EYPT
+ 0.8
SVRA
KURA
+ 0.68
GHRS
LENZ
+ 0.61
PROK
RZLT
+ 0.57
GHRS
  

High negative correlations

PROK
- 0.74
TYRA
LENZ
- 0.72
SVRA
PROK
- 0.72
SVRA
RZLT
- 0.68
TYRA
EYPT
- 0.67
RZLT
LENZ
- 0.67
TYRA

Risk-Adjusted Indicators

There is a big difference between Nanobiotix Stock performing well and Nanobiotix Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Nanobiotix's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
GHRS  2.84 (0.09)(0.01) 0.01  3.96 
(2.78)
 5.49 
(6.27)
 22.73 
SPRY  3.81  0.13  0.06  0.09  4.10 
(4.68)
 7.93 
(7.84)
 24.30 
SVRA  3.11  0.84  0.36  0.37  2.07 
(4.35)
 8.43 
(4.48)
 24.50 
TYRA  2.85  1.12  0.39  1.80  2.00 
(3.41)
 6.21 
(3.06)
 34.11 
RZLT  6.31  0.00  0.00  0.06  0.00 
 0.00 
 15.82 
(8.99)
 99.29 
KURA  3.21  0.21  0.07  0.16  3.13 
(3.84)
 6.96 
(4.80)
 22.15 
ABUS  2.37  0.08  0.05  0.09  2.67 
(2.64)
 5.10 
(4.04)
 13.51 
PROK  3.96 (0.32) 0.00 (0.08) 0.00 
 0.00 
 6.82 
(8.95)
 25.70 
LENZ  4.11 (1.62) 0.00 (1.54) 0.00 
 0.00 
 6.94 
(10.16)
 40.02 
EYPT  3.20  0.46  0.10  0.99  3.91 
(3.25)
 7.21 
(4.89)
 19.30 
All Fundamental Data

Nanobiotix Competitive Analysis

The better you understand Nanobiotix competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Nanobiotix's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Nanobiotix's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NBTX GHRS SPRY SVRA TYRA RZLT KURA ABUS PROK LENZ
 6.69 
 23.12 
Nanobiotix
 1.60 
 12.70 
GHRS
 0.09 
 11.65 
ARS
 1.31 
 6.03 
Savara
 3.34 
 26.29 
Tyra
 7.76 
 2.36 
Rezolute
 1.66 
 10.39 
Kura
 4.11 
 4.81 
Arbutus
 1.82 
 2.24 
ProKidney
 0.74 
 16.00 
LENZ
Market Volatility
(90 Days Market Risk)
Slightly risky
Not too volatile
Somewhat reliable
Slightly risky
Not too volatile
Extremely Dangerous
Somewhat reliable
Slightly risky
Very risky
Somewhat reliable
Market Performance
(90 Days Performance)
Mild
Weakest
Mild
Solid
Solid
Weakest
Soft
Mild
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
High
High
Low
Small
Low
Low
Small
High
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Fairly Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Strong Buy
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Sell
Sell
Strong Sell
Strong Hold
Buy
Strong Sell
Cautious Hold
Sell
Strong Sell
Strong Sell
Current Ratio
1.71
86.02
N/A
39.23
50.83
61.78
25.73
5.29
0.74
N/A
Net Asset
67.42 M
188.27 M
351.15 M
212.88 M
363.56 M
175.49 M
760.16 M
131.71 M
441.07 M
215.3 M
Profit Margin
N/A
N/A
-0.56
N/A
N/A
N/A
-2.08
-2.89
N/A
N/A
EBITDA
(58.32 M)
(38.6 M)
(3 M)
(102.27 M)
(103.66 M)
(79.86 M)
(169.5 M)
(68.4 M)
(158.49 M)
(49.71 M)
Operating Margin
0.0306
N/A
-1.64
N/A
N/A
N/A
-3.86
-15.68
-176.13
-1.51
Current Valuation
1.12 B
487.44 M
960.15 M
1.15 B
1.09 B
52.33 M
359.12 M
795.76 M
43.91 M
303.18 M
Price To Book
65.02
2.66
7.85
13.17
4.84
1.53
2.6
11.48
97.15
2.6
Retained Earnings
(68.13 M)
(106.45 M)
(123.31 M)
(489.25 M)
(251.31 M)
(403.86 M)
(895.42 M)
(1.35 B)
(1.2 B)
(145.01 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
86.87 M
183.88 M
N/A
N/A
Beta
0.48
0.97
0.8
0.22
1.09
0.22
0.21
0.66
1.82
N/A
Number Of Employees
103
50
162
59
60
75
192
44
204
13
Shares Outstanding
48.38 M
62.03 M
98.85 M
203.47 M
53.37 M
92.73 M
87.02 M
192.32 M
141.55 M
31.29 M
Cash Flow From Operations
(19.55 M)
(42.28 M)
13.55 M
(89.09 M)
(69.77 M)
(69.08 M)
134.32 M
(64.85 M)
(126.35 M)
(59.39 M)
Total Debt
50.9 M
624 K
42 K
26.73 M
6.22 M
1.61 M
16.59 M
1.29 M
3.24 M
1.38 M
Return On Equity
-1.99
-0.18
-0.46
-0.79
-0.35
-0.59
-0.65
-0.46
-0.42
-0.29
Return On Asset
-0.42
-0.14
-0.19
-0.4
-0.23
-0.37
-0.27
-0.16
-0.26
-0.2
Number Of Shares Shorted
31.22 K
2.17 M
21.59 M
20.19 M
4.24 M
12.22 M
8.22 M
10.74 M
13.81 M
7.17 M
Book Value Per Share
-1.68
4.7
1.49
0.45
5.26
1.62
2.79
0.4
-7.41
6.78
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
5.05 M
10.58 M
N/A
N/A
Total Asset
67.42 M
188.27 M
351.15 M
212.88 M
363.56 M
175.49 M
760.16 M
131.71 M
441.07 M
215.3 M
Short Ratio
0.64
8.46
10.04
5.61
7.2
1.18
5.22
9.27
11.58
6.12
Target Price
15.86
30.38
28.83
10.81
33.0
4.13
33.0
5.74
6.5
53.71
Debt To Equity
N/A
N/A
N/A
0.21
0.009
0.001
0.013
0.016
5.66
N/A
Shares Owned By Institutions
11.7
71.97
87.34
83.5
96.81
89.49
97.54
62.56
28.54
97.05
Market Capitalization
1.05 B
775.37 M
1.15 B
1.24 B
1.36 B
203.07 M
904.11 M
888.54 M
661.84 M
504.39 M
Price To Earning
N/A
N/A
N/A
-2.46
-3.33
N/A
-9.03
-1.16
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
0.28
N/A
N/A
N/A
N/A
N/A
Price To Sales
103.2
N/A
8.06
131146.0
N/A
N/A
8.69
60.83
889.56
28.82
Net Income
(68.13 M)
(38.96 M)
8 M
(95.88 M)
(86.48 M)
(74.41 M)
(173.98 M)
(69.92 M)
(163.34 M)
(49.77 M)
Earnings Per Share
-1.28
-0.73
-0.81
-0.53
-1.88
-0.94
-2.48
-0.23
-0.55
-2.06
Shares Owned By Insiders
N/A
26.77
16.82
4.72
3.19
10.51
1.98
21.8
25.38
2.53
Revenue
(11.61 M)
N/A
89.15 M
N/A
N/A
N/A
53.88 M
6.17 M
76 K
N/A
Working Capital
2.53 M
145.27 M
310.86 M
187.41 M
332.87 M
159.23 M
666.12 M
111.7 M
359.67 M
201.51 M
Cash And Equivalents
63.02 M
265.38 M
N/A
142.62 M
275.11 M
150.41 M
450.26 M
150.2 M
21.88 M
N/A
Cash Per Share
1.81
5.1
N/A
1.25
6.61
3.87
6.73
1.0
0.36
N/A
Gross Profit
10.16 M
N/A
114.87 M
(83.8 M)
N/A
N/A
(120.28 M)
(14.44 M)
744 K
17.5 M
Day Typical Price
22.92
12.6
11.71
6.05
26.02
2.3
10.31
4.82
2.21
15.99
Accumulation Distribution
0.0496
0.0244
0.0343
0.0468
0.0398
0.0882
0.0298
0.0911
0.0357
0.0247
Market Facilitation Index
1.16
0.31
0.41
0.29
1.05
0.21
0.31
0.46
0.08
0.4
Daily Balance Of Power
1.25
0.6452
0.0244
(0.28)
0.8095
0.8095
0.5484
0.413
0.5
(0.30)
Period Momentum Indicator
1.45
0.2
0.01
(0.08)
0.85
0.17
0.17
0.19
0.04
(0.12)
Rate Of Daily Change
1.07
1.02
1.0
0.99
1.03
1.08
1.02
1.04
1.02
0.99
Day Median Price
22.82
12.56
11.74
6.06
25.89
2.28
10.27
4.82
2.2
15.98
Price Action Indicator
1.03
0.24
(0.08)
(0.07)
0.83
0.17
0.21
0.085
0.06
(0.04)
Relative Strength Index
50.23
39.25
54.15
57.89
64.39
25.26
41.91
54.23
49.6
21.3
Coefficient Of Variation
1569.28
13945.37
1570.98
446.84
397.76
(218,210)
1367.46
1509.01
(2,736)
(405.82)
Mean Deviation
5.67
2.84
3.81
3.11
2.85
6.31
3.21
2.37
3.96
4.11
Jensen Alpha
0.4245
(0.09)
0.1338
0.8378
1.12
(0)
0.2094
0.0842
(0.32)
(1.62)
Total Risk Alpha
(0.05)
(0.26)
(0.04)
0.665
0.8304
(0.94)
0.008
(0.02)
(0.56)
(2.01)
Sortino Ratio
0.0649
(0.01)
0.0603
0.3643
0.3886
N/A
0.0748
0.0479
N/A
N/A
Downside Variance
57.52
17.49
18.73
6.33
8.0
N/A
11.07
7.84
N/A
N/A
Standard Deviation
8.64
4.02
5.02
4.36
4.6
13.39
4.2
2.91
5.18
6.35
Kurtosis
3.62
2.06
0.8187
3.21
14.2
29.48
2.07
(0.12)
0.5511
5.03
Potential Upside
13.18
5.49
7.93
8.43
6.21
15.82
6.96
5.1
6.82
6.94
Treynor Ratio
0.2262
0.0088
0.0856
0.3687
1.8
0.0561
0.1641
0.0901
(0.08)
(1.54)
Maximum Drawdown
51.64
22.73
24.3
24.5
34.11
99.29
22.15
13.51
25.7
40.02
Variance
74.65
16.15
25.18
18.98
21.2
179.4
17.68
8.46
26.85
40.29
Market Risk Adjusted Performance
0.2362
0.0188
0.0956
0.3787
1.81
0.0661
0.1741
0.1001
(0.07)
(1.53)
Risk Adjusted Performance
0.0541
0.0133
0.0535
0.1663
0.1858
0.0092
0.0599
0.0543
(0.02)
(0.16)
Skewness
0.7433
0.4146
0.4496
1.48
2.84
(4.25)
1.08
(0)
(0.49)
(1.40)
Semi Deviation
7.19
3.96
4.1
2.07
2.0
N/A
3.13
2.67
N/A
N/A
Information Ratio
0.0569
(0.01)
0.052
0.2103
0.2387
(0)
0.0592
0.0461
(0.05)
(0.26)
Value At Risk
(13.07)
(6.27)
(7.84)
(4.48)
(3.06)
(8.99)
(4.80)
(4.04)
(8.95)
(10.16)
Expected Short fall
(6.60)
(2.78)
(4.68)
(4.35)
(3.41)
N/A
(3.84)
(2.64)
N/A
N/A
Downside Deviation
7.58
4.18
4.33
2.52
2.83
N/A
3.33
2.8
N/A
N/A
Semi Variance
51.73
15.65
16.8
4.27
4.0
N/A
9.83
7.13
N/A
N/A

Nanobiotix Competition Performance Charts

Five steps to successful analysis of Nanobiotix Competition

Nanobiotix's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Nanobiotix in relation to its competition. Nanobiotix's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Nanobiotix in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Nanobiotix's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Nanobiotix, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Nanobiotix position

In addition to having Nanobiotix in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Trump Equities Thematic Idea Now

Trump Equities
Trump Equities Theme
Stocks that have significantly increased in valuation since Trump was elected president of the United States. The Trump Equities theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Trump Equities Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Nanobiotix Stock Analysis

When running Nanobiotix's price analysis, check to measure Nanobiotix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobiotix is operating at the current time. Most of Nanobiotix's value examination focuses on studying past and present price action to predict the probability of Nanobiotix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobiotix's price. Additionally, you may evaluate how the addition of Nanobiotix to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY